Sutimlimab provides sustained improvements in patient-reported outcomes and quality of life in patients with cold agglutinin disease: open-label extension of the randomized, Phase 3 CADENZA Study

Blood(2023)

引用 0|浏览5
暂无评分
关键词
cold agglutinin disease,patient-reported,open-label
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要